GRANT score for predicting disease-free survival in kidney cancer

In this retrospective study conducted at various hospitals in Italy, the GRANT (GRade, Age, Nodes, and Tumour) and the UISS (University of California Los Angeles Integrated Staging System) scores were compared in 134 patients with renal cell carcinoma (RCC) who had a nephrectomy. These scores are used to predict outcomes in patients with localised RCC. […]

read more

Platelet-to-lymphocyte ratio predicts survival outcomes in kidney cancer

In this study, the researchers looked at the association between a high platelet-to-lymphocyte ratio in the blood and the prognosis of patients with metastatic renal cell carcinoma (RCC). Data from 1,505 patients with metastatic RCC were retrospectively analysed. There were 921 patients with a high platelet-to-lymphocyte ratio and and 584 patients with a low ratio. […]

read more

Biomarkers for kidney cancer: current and future strategies

An educational symposium was held from 8-10 August as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting. In his presentation, Dr McGregor from the Dana-Farber Cancer Institute, Boston, USA describes prognostic biomarkers that give an indication of the outcome of the patient on a particular treatment, and predictive biomarkers that predict a […]

read more

Blood tumour biomarker for kidney cancer survival

Researchers are constantly looking for biomarkers to help predict which patients will respond to each kidney cancer treatment. A study in Scandinavia has discovered a protein called tumour associated trypsin inhibitor (TATI) that is a biomarker for several tumours and for inflammation. High levels of TATI in the blood predicts an unfavourable outcome for many […]

read more

Inflammatory biomarkers for non-metastatic kidney cancer

This study looked at inflammatory biomarkers in the blood for the diagnosis of non-metastatic renal cell carcinoma (RCC).  Inflammation is known to be associated with cancer, and there have been a number of studies that have looked at the relationship between cancer and inflammatory biomarkers. Inflammatory biomarkers such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte […]

read more

Inflammatory biomarkers to predict outcomes in kidney cancer

There still remains the need for a reliable biomarker to predict outcomes for advanced kidney cancer patients. Scientists have been working hard to try to identify biomarkers that can predict clinical outcomes and the course of the disease in people with metastatic renal cell carcinoma (RCC). A recent study published in Pathology Oncology Research this […]

read more

Potential biomarker to predict outcomes in metastatic kidney cancer

A recent study published in Targeted Oncology last month investigates the role of an enzyme called γ-glutamyltransferase (GGT) as a potential biomarker for metastatic renal cell carcinoma (RCC). High levels of GGT in the blood has been linked with poor survival in various cancers; however, there are no data for metastatic RCC patients. This study […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

A potential biomarker for survival for non-metastatic kidney cancer

A recent study published in the journal International Urology and Nephrology this month evaluates mean platelet volume-to-lymphocyte ratio (MPVLR) as a biomarker for survival in patients undergoing nephrectomy for non-metastatic clear cell renal cell carcinoma (ccRCC). In the study, 344 patients with proven ccRCC that has not spread (non-metastatic) were treated with radical or partial […]

read more

Predictive biomarkers for kidney cancer

At the Society of Urologic Oncology (SUO) conference in Washington, USA last week, Dr Joshua Lang discussed the future of predictive biomarkers in renal cell carcinoma (RCC). The treatment of kidney cancer is evolving with first-line combination therapies, including nivolumab plus ipilimumab and axitinib plus pembrolizumab, and first-line drug options that depend on risk of […]

read more
Showing 1 to 10 of 24 results
  TOP